BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...Ebeling as COO, a new position. He was VP and CTO of Abbott Laboratories (NYSE:ABT). DalCor...
...NASDAQ:ALKS). Robin Sawka, BioCentury Staff Constellation Pharmaceuticals Inc. Inspire Medical Systems Inc. Akcea Therapeutics Inc. iTeos Therapeutics S.A. Amplyx Pharmaceuticals Inc. Antengene Corp. DalCor Pharma U.K. Ltd. SwanBio...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Ltd. $178.1 3/16/17 Off-the-shelf CAR-NKT cell therapies Cancer Symphogen A/S $155.2 10/22/15 Antibodies Cancer, infectious DalCor Pharma U.K. Ltd....
BioCentury | May 18, 2018
Finance

China comes to Europe

...6/24/16 Kymab Group Ltd. $190.0 11/24/16 Autolus Ltd. $180.9 9/26/17 Cell Medica Ltd. $178.1 3/16/17 DalCor Pharma U.K. Ltd....
BioCentury | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

...appointed Charles Dimmler as chairman. He was vice chairman at Torreya Partners LLC. Cardiovascular company DalCor Pharma U.K. Ltd....
BioCentury | Jun 27, 2017
Clinical News

Merck's CETP inhibitor meets in CV outcomes study

...heart disease following a recent acute coronary syndrome (ACS) (see BioCentury, May 21, 2012) . DalCor Pharma U.K. Ltd....
...product from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) (see BioCentury, Sept. 21, 2015) . Chris Lieu AMG 899 anacetrapib dalcetrapib evacetrapib TA-8995 Amgen Inc. DalCor Pharma U.K. Ltd. Merck...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...Group Ltd. $220.1 11/24/16 Symphogen A/S $201.5 10/22/15 CRISPR Therapeutics AG (NASDAQ:CRSP) (A) $198.6 06/24/16 DalCor Pharma U.K. Ltd....
...S.a.r.l. (Switzerland) Undisclosed $105.0 Auven Therapeutics Management, Wild Family Office, AstraZeneca plc, other undisclosed investors DalCor Pharma U.K. Ltd....
BioCentury | May 16, 2016
Finance

Global ambitions

...& Melinda Gates Foundation, private investor Oxford Nanopore Technologies Ltd. (U.K.) Undisclosed $109 Undisclosed investors DalCor Pharma U.K. Ltd....
BioCentury | Apr 25, 2016
Finance

Saved by a SNP

...At a time when venture dollars for cardiovascular companies are dwindling, DalCor Pharma U.K. Ltd. found a syndicate willing...
...steadily fallen since then. For the past three years the slice has been only 5%. DalCor...
...Québec, the Fonds de solidarité FTQ, CTI Life Sciences and undisclosed other investors. This month, DalCor...
BioCentury | Apr 25, 2016
Financial News

DalCor completes venture financing

DalCor Pharma U.K. Ltd. , London, U.K. Business: Cardiovascular Date completed: 2016-04-19 Type: Venture financing Raised: $100 million Investors: Sanderling; Caisse de Depot et Placement du Quebec; Fonds de solidarite FTQ; CTI Life Sciences Fund; and...
BioCentury | Apr 20, 2016
Financial News

DalCor raises $100M in series B

...treat cardiovascular disease. DalCor in-licensed the molecule from Roche (SIX:ROG; OTCQX:RHHBY) last year. This month, DalCor...
...2012 after it failed in a Phase III study to treat coronary heart disease (CHD). DalCor...
...the Roche study showed dalcetrapib had efficacy in the subset of patients DalCor is pursuing. DalCor...
Items per page:
1 - 10 of 12
BioCentury | Jun 10, 2020
Management Tracks

iTeos builds out team with CFO, R&D VP; plus Constellation, SwanBio, Akcea, Amplyx, Antengene and more

...Ebeling as COO, a new position. He was VP and CTO of Abbott Laboratories (NYSE:ABT). DalCor...
...NASDAQ:ALKS). Robin Sawka, BioCentury Staff Constellation Pharmaceuticals Inc. Inspire Medical Systems Inc. Akcea Therapeutics Inc. iTeos Therapeutics S.A. Amplyx Pharmaceuticals Inc. Antengene Corp. DalCor Pharma U.K. Ltd. SwanBio...
BioCentury | May 24, 2019
Finance

How Europe’s hotspots of innovation could fuel its rise as a global player in new modalities

...Ltd. $178.1 3/16/17 Off-the-shelf CAR-NKT cell therapies Cancer Symphogen A/S $155.2 10/22/15 Antibodies Cancer, infectious DalCor Pharma U.K. Ltd....
BioCentury | May 18, 2018
Finance

China comes to Europe

...6/24/16 Kymab Group Ltd. $190.0 11/24/16 Autolus Ltd. $180.9 9/26/17 Cell Medica Ltd. $178.1 3/16/17 DalCor Pharma U.K. Ltd....
BioCentury | Apr 10, 2018
Company News

Management tracks: Immunomedics, argenx

...appointed Charles Dimmler as chairman. He was vice chairman at Torreya Partners LLC. Cardiovascular company DalCor Pharma U.K. Ltd....
BioCentury | Jun 27, 2017
Clinical News

Merck's CETP inhibitor meets in CV outcomes study

...heart disease following a recent acute coronary syndrome (ACS) (see BioCentury, May 21, 2012) . DalCor Pharma U.K. Ltd....
...product from Mitsubishi Tanabe Pharma Corp. (Tokyo:4508) (see BioCentury, Sept. 21, 2015) . Chris Lieu AMG 899 anacetrapib dalcetrapib evacetrapib TA-8995 Amgen Inc. DalCor Pharma U.K. Ltd. Merck...
BioCentury | May 26, 2017
Finance

Europe’s bellwether challenge

...Group Ltd. $220.1 11/24/16 Symphogen A/S $201.5 10/22/15 CRISPR Therapeutics AG (NASDAQ:CRSP) (A) $198.6 06/24/16 DalCor Pharma U.K. Ltd....
...S.a.r.l. (Switzerland) Undisclosed $105.0 Auven Therapeutics Management, Wild Family Office, AstraZeneca plc, other undisclosed investors DalCor Pharma U.K. Ltd....
BioCentury | May 16, 2016
Finance

Global ambitions

...& Melinda Gates Foundation, private investor Oxford Nanopore Technologies Ltd. (U.K.) Undisclosed $109 Undisclosed investors DalCor Pharma U.K. Ltd....
BioCentury | Apr 25, 2016
Finance

Saved by a SNP

...At a time when venture dollars for cardiovascular companies are dwindling, DalCor Pharma U.K. Ltd. found a syndicate willing...
...steadily fallen since then. For the past three years the slice has been only 5%. DalCor...
...Québec, the Fonds de solidarité FTQ, CTI Life Sciences and undisclosed other investors. This month, DalCor...
BioCentury | Apr 25, 2016
Financial News

DalCor completes venture financing

DalCor Pharma U.K. Ltd. , London, U.K. Business: Cardiovascular Date completed: 2016-04-19 Type: Venture financing Raised: $100 million Investors: Sanderling; Caisse de Depot et Placement du Quebec; Fonds de solidarite FTQ; CTI Life Sciences Fund; and...
BioCentury | Apr 20, 2016
Financial News

DalCor raises $100M in series B

...treat cardiovascular disease. DalCor in-licensed the molecule from Roche (SIX:ROG; OTCQX:RHHBY) last year. This month, DalCor...
...2012 after it failed in a Phase III study to treat coronary heart disease (CHD). DalCor...
...the Roche study showed dalcetrapib had efficacy in the subset of patients DalCor is pursuing. DalCor...
Items per page:
1 - 10 of 12